HC Wainwright Reaffirms "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS)

HC Wainwright reiterated their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS - Free Report) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.

Separately, Piper Sandler reiterated an "overweight" rating and set a $7.00 target price on shares of Alpha Tau Medical in a research note on Thursday, August 15th.

Alpha Tau Medical Stock Performance

Shares of NASDAQ DRTS traded up $0.01 during mid-day trading on Friday, reaching $2.31. 13,642 shares of the company's stock were exchanged, compared to its average volume of 31,173. The firm has a market capitalization of $160.94 million, a price-to-earnings ratio of -5.34 and a beta of 0.77. Alpha Tau Medical has a 52 week low of $1.75 and a 52 week high of $3.40. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.66 and a quick ratio of 11.60. The firm has a 50-day moving average price of $2.28 and a two-hundred day moving average price of $2.30.

Institutional Investors Weigh In On Alpha Tau Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Aptus Capital Advisors LLC raised its stake in Alpha Tau Medical by 83.7% in the 2nd quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company's stock valued at $56,000 after acquiring an additional 10,000 shares during the period. Caprock Group LLC purchased a new position in Alpha Tau Medical during the 2nd quarter valued at about $59,000. Financial Guidance Group Inc. grew its holdings in shares of Alpha Tau Medical by 83.7% during the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company's stock worth $56,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Levin Capital Strategies L.P. grew its holdings in shares of Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company's stock worth $999,000 after purchasing an additional 8,641 shares in the last quarter. 2.65% of the stock is currently owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.